Therapeutic agent for ophthalmic diseases
A pharmaceutical composition using 7-amino-2-(hetero)arylquinoline-5,8-dione derivatives addresses the inadequacies of current treatments for diabetic retinopathy by inhibiting TGase2 activity, effectively reducing vascular leakage and metabolic disorders in diabetic retinopathy.
WO2026134362A1PCT designated stage Publication Date: 2026-06-25DAEGU GYEONGBUK MEDICAL INNOVATION FOUND
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DAEGU GYEONGBUK MEDICAL INNOVATION FOUND
- Filing Date
- 2024-12-16
- Publication Date
- 2026-06-25
Smart Images
Figure KR2024020393_25062026_PF_FP_ABST
Abstract
The present invention relates to a pharmaceutical composition comprising a 7-amino-2-(hetero)arylquinoline-5,8-dione derivative compound, a stereoisomer thereof, a hydrate thereof, or a salt thereof as an active ingredient for preventing or treating ophthalmic diseases. When a retinopathy model is established by subjecting retinal vascular endothelial cells to various treatments and the compound is applied thereto, an effect of preventing vascular leakage is confirmed, in vivo, thereby indicating that the compound can be usefully employed as a therapeutic agent for ophthalmic diseases.
Need to check novelty before this filing date? Find Prior Art